Get the Stockscreener App
27.68
0.16%
-0.03
Quidelortho Corporation stock is traded at $27.68, with a volume of 550.96K.
It is down -0.16% in the last 24 hours and down -7.72% over the past month.
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
See More
Previous Close:
$27.71
Open:
$27.34
24h Volume:
550.96K
Relative Volume:
0.44
Market Cap:
$1.88B
Revenue:
$2.74B
Net Income/Loss:
$-441.40M
P/E Ratio:
-4.2324
EPS:
-6.54
Net Cash Flow:
$13.00M
1W Performance:
-1.86%
1M Performance:
-7.72%
6M Performance:
-5.00%
1Y Performance:
-29.23%
1-Day Range:
$26.79
$27.98
1-Week Range:
$26.17
$28.63
52-Week Range:
$22.05
$49.45
Quidelortho Corporation Stock (QDEL) Company Profile
Name
Quidelortho Corporation
Sector
Industry
Phone
(858) 552-1100
Address
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
27.66 | 1.88B | 2.74B | -441.40M | 13.00M | -6.54 |
|
ABT
Abbott Laboratories
|
125.34 | 215.34B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.58 | 146.15B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
361.18 | 136.97B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.04 | 115.69B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.95 | 48.77B | 5.88B | 1.34B | 577.90M | 2.3455 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-25 | Downgrade | Citigroup | Buy → Neutral |
| May-08-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Sep-19-24 | Resumed | UBS | Neutral |
| Sep-05-24 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-04-24 | Downgrade | UBS | Neutral → Sell |
| Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-14-22 | Upgrade | UBS | Sell → Neutral |
| Sep-19-22 | Initiated | Citigroup | Neutral |
| Jul-20-22 | Initiated | UBS | Sell |
| Jun-17-22 | Resumed | JP Morgan | Neutral |
| Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-18 | Reiterated | Barclays | Overweight |
| Jan-04-18 | Upgrade | CL King | Neutral → Buy |
| Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
| Feb-17-17 | Initiated | CL King | Neutral |
| Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-18-16 | Reiterated | Barclays | Overweight |
| Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-02-15 | Initiated | Barclays | Overweight |
| Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
| Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
Quidelortho Corporation Stock (QDEL) Latest News
QuidelOrtho (QDEL): Assessing Valuation After FDA Clearance for High-Sensitivity Troponin I Assay - simplywall.st
US FDA grants 510(k) clearance to QuidelOrtho’s VITROS hs Troponin I Assay - Pharmabiz.com
How to build a dashboard for QuidelOrtho Corporation stock2025 Key Lessons & Free Accurate Trade Setup Notifications - newser.com
Can QuidelOrtho Corporation stock deliver surprise earnings beatMarket Activity Recap & Risk Managed Trade Strategies - newser.com
Is QuidelOrtho Corporation trending in predictive chart modelsEarnings Recap Report & Fast Entry Momentum Alerts - newser.com
Will QuidelOrtho Corporation benefit from macro trendsJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - newser.com
Published on: 2025-11-04 00:39:36 - newser.com
QuidelOrtho receives FDA clearance for high-sensitivity troponin test By Investing.com - Investing.com India
What candlestick patterns are forming on QuidelOrtho Corporation2025 Technical Patterns & Free Community Consensus Stock Picks - newser.com
QuidelOrtho (QDEL) Q3 Earnings: What To Expect - Yahoo! Finance Australia
QuidelOrtho Gets FDA Clearance for Cardiac Assay - MarketScreener
QuidelOrtho Corporation’s volatility index tracking explainedRate Cut & High Win Rate Trade Tips - newser.com
Will QuidelOrtho Corporation stock reach Wall Street targetsJuly 2025 Snapshot & Reliable Entry Point Trade Alerts - newser.com
Predicting QuidelOrtho Corporation trend using moving averages2025 Short Interest & Reliable Price Action Trade Plans - newser.com
Is QuidelOrtho Corporation stock near bottom after declineWeekly Trade Analysis & Fast Gaining Stock Reports - newser.com
Quidelortho receives FDA 510(k) clearance for VITROS Immunodiagnostic Products hs Troponin I assay - MarketScreener
Analyzing recovery setups for QuidelOrtho Corporation investorsJuly 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Will QuidelOrtho Corporation stock split attract more investorsJuly 2025 News Drivers & Accurate Trade Setup Notifications - newser.com
Real time scanner hits for QuidelOrtho Corporation explainedWeekly Trend Recap & Long-Term Safe Investment Plans - newser.com
QuidelOrtho receives FDA clearance for high-sensitivity troponin test - Investing.com
What technical models suggest about QuidelOrtho Corporation’s comebackOptions Play & Weekly Return Optimization Plans - newser.com
QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay - PR Newswire
Published on: 2025-11-03 04:51:46 - newser.com
Why QuidelOrtho Corporation stock remains on watchlists2025 Market Trends & Long-Term Growth Stock Strategies - newser.com
Analyzing drawdowns of QuidelOrtho Corporation with statistical toolsPortfolio Performance Report & Technical Pattern Based Signals - newser.com
Volume spikes in QuidelOrtho Corporation stock – what they mean2025 Fundamental Recap & AI Driven Stock Reports - newser.com
Is QuidelOrtho Corporation (QL1A) stock a momentum leaderStop Loss & Weekly Top Stock Performers List - newser.com
Will QuidelOrtho Corporation stock benefit from infrastructure spendingQuarterly Earnings Summary & Stepwise Entry/Exit Trade Alerts - newser.com
QuidelOrtho Faces Critical Earnings Test Amid Diverging Analyst Views - AD HOC NEWS
Will QuidelOrtho Corporation stock recover faster than marketPrice Action & Daily Stock Momentum Reports - newser.com
Is QuidelOrtho Corporation (QL1A) stock undervalued at current price2025 Retail Activity & Real-Time Volume Triggers - newser.com
Regression analysis insights on QuidelOrtho Corporation performanceEarnings Recap Summary & Smart Money Movement Alerts - newser.com
Published on: 2025-11-02 01:25:49 - newser.com
How hedge fund analytics apply to QuidelOrtho Corporation stock2025 Trade Ideas & Stepwise Trade Signal Implementation - newser.com
Brighton Jones LLC Makes New $384,000 Investment in QuidelOrtho Corporation $QDEL - MarketBeat
Is QuidelOrtho Corporation (QL1A) stock testing key supportEarnings Summary Report & Risk Managed Investment Signals - newser.com
Quidelortho Corporation Stock (QDEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.26%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):